Journal
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
Volume 7, Issue 4, Pages 115-121Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1759720X15588514
Keywords
belimumab; lupus treatment; systemic lupus erythematosus
Categories
Ask authors/readers for more resources
Belimumab (Benlysta (R)) is a fully humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was approved by the US Food and Drug Administration and the European Medicines Evaluation Agency for treatment of autoantibody-positive systemic lupus erythematosus (SLE) in adults. This review discusses the key findings of the phase III trials, post hoc analyses, and real-world postmarketing use of belimumab in the routine care of SLE patients. It also highlights the safety profile of belimumab and gives insight into its potential use to treat childhood-onset SLE. It concludes with a discussion of the current clinical trials investigating belimumab in specific SLE disease states and a look to the future with novel targeted B-cell therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available